PlaqueTec has developed the first-of-its-kind PlaqueTec Liquid Biopsy System™ (LBS), a platform technology that can help to resolve processes that lead to coronary artery disease (CAD). Since 2012, PlaqueTec has validated the LBS in two clinical studies and identified numerous biomarkers that are associated with CAD. PlaqueTec is using these biomarkers to build a database for clinicians, researchers, and biopharmaceutical companies to conduct translational research and develop next-generation personalised CAD therapies. The PlaqueTec LBS received a CE Mark in July 2014. The company is funded by IPEX Capital and guided by a strong network of scientific advisors and clinicians.